Thrombocytopenia is a common laboratory finding in critically ill patients admitted to the intensive care unit. Potential etiologies of thrombocytopenia are myriad, ranging from acute disease processes and concomitant conditions to exposures and drugs. The mechanism of decreased platelet counts can also be varied: laboratory measurement may be spurious, platelet production may be decreased, or platelet destruction or sequestration may be increased. In addition to evaluation for the cause of thrombocytopenia, the clinician must also guard against spontaneous bleeding due to thrombocytopenia, prophylax against bleeding resulting from an invasive procedure performed in the setting of thrombocytopenia, and treat active bleeding related to thrombocytopenia.
CrowtherMACookDJMeadeMO. Thrombocytopenia in medical-surgical critically ill patients: prevalence, incidence, and risk factors. J Crit Care. 2005;20(4):348–353.
2.
StephanFHollandeJRichardOCheffiAMaier-RedelspergerMFlahaultA. Thrombocytopenia in a surgical ICU. Chest. 1999;115(5):1363–1370.
3.
HanesSDQuarlesDABoucherBA. Incidence and risk factors of thrombocytopenia in critically ill trauma patients. Ann Pharmacother. 1997;31(3):285–289.
4.
SlichterSJKaufmanRMAssmannSF. Dose of prophylactic platelet transfusions and prevention of hemorrhage. N Engl J Med. 2010;362(7):600–613.
5.
TrowbridgeEAMartinJFSlaterDN. Evidence for a theory of physical fragmentation of megakaryocytes, implying that all platelets are produced in the pulmonary circulation. Thromb Res. 1982;28(4):461–475.
6.
BrecherGCronkiteEP. Morphology and enumeration of human blood platelets. J Appl Physiol. 1950;3(6):365–377.
7.
BessmanJDWilliamsLJGilmerPRJr. Mean platelet volume. The inverse relation of platelet size and count in normal subjects, and an artifact of other particles. Am J Clin Pathol. 1981;76(3):289–293.
8.
LiJXiaYKuterDJ. Interaction of thrombopoietin with the platelet c-mpl receptor in plasma: binding, internalization, stability and pharmacokinetics. Br J Haematol. 1999;106(2):345–356.
9.
AlberioLFriesePClemetsonKJDaleGL. Collagen response and glycoprotein VI function decline progressively as canine platelets age in vivo. Thromb Haemost. 2002;88(3):510–516.
10.
PengJFriesePHeilmannEGeorgeJNBursteinSADaleGL. Aged platelets have an impaired response to thrombin as quantitated by P-selectin expression. Blood. 1994;83(1):161–166.
11.
JacksonSP. The growing complexity of platelet aggregation. Blood. 2007;109(12):5087–5095.
12.
StanworthSJDentonKMonteathJPattonWN. Automated counting of platelets on the Bayer ADVIA 120 analyser. Clin Lab Haematol. 1999;21(2):113–117.
FiorinFSteffanAPradellaPBizzaroNPotenzaRDe AngelisV. IgG platelet antibodies in EDTA-dependent pseudothrombocytopenia bind to platelet membrane glycoprotein IIb. Am J Clin Pathol. 1998;110(2):178–183.
15.
BartelsPCSchoorlMLombartsAJ. Screening for EDTA-dependent deviations in platelet counts and abnormalities in platelet distribution histograms in pseudothrombocytopenia. Scand J Clin Lab Invest. 1997;57(7):629–636.
16.
RodgersRPLevinJ. A critical reappraisal of the bleeding time. Semin Thromb Hemost. 1990;16(1):1–20.
17.
HaywardCPPaiMLiuY. Diagnostic utility of light transmission platelet aggregometry: results from a prospective study of individuals referred for bleeding disorder assessments. J Thromb Haemost. 2009;7(4):676–684.
18.
SmithJWSteinhublSRLincoffAM. Rapid platelet-function assay: an automated and quantitative cartridge-based method. Circulation. 1999;99(5):620–625.
19.
KunduSKHeilmannEJSioRGarciaCDavidsonRMOstgaardRA. Description of an in vitro platelet function analyzer—PFA-100. Semin Thromb Hemost. 1995;21(suppl 2):106–112.
20.
SteinerRWCogginsCCarvalhoAC. Bleeding time in uremia: a useful test to assess clinical bleeding. Am J Hematol. 1979;7(2):107–117.
21.
Di MinnoGMartinezJMcKeanMLDe La RosaJBurkeJFMurphyS. Platelet dysfunction in uremia. Multifaceted defect partially corrected by dialysis. Am J Med. 1985;79(5):552–559.
22.
MhawechPSaleemA. Inherited giant platelet disorders. Classification and literature review. Am J Clin Pathol. 2000;113(2):176–190.
23.
MaroneGAlbiniFdi MartinoLQuattrinSPotoSCondorelliM. The Wiskott-Aldrich syndrome: studies of platelets, basophils and polymorphonuclear leucocytes. Br J Haematol. 1986;62(4):737–745.
24.
PhillipsDRAginPP. Platelet membrane defects in Glanzmann's thrombasthenia. Evidence for decreased amounts of two major glycoproteins. J Clin Invest. 1977;60(3):535–545.
25.
ElliottMATefferiA. Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. Br J Haematol. 2005;128(3):275–290.
26.
LivioMGottiEMarchesiDMeccaGRemuzziGde GaetanoG. Uraemic bleeding: role of anaemia and beneficial effect of red cell transfusions. Lancet. 1982;2(8306):1013–1015.
27.
ZeiglerZRMegaludisAFraleyDS. Desmopressin (d-DAVP) effects on platelet rheology and von Willebrand factor activities in uremia. Am J Hematol. 1992;39(2):90–95.
28.
MannucciPMRemuzziGPusineriF. Deamino-8-D-arginine vasopressin shortens the bleeding time in uremia. N Engl J Med. 1983;308(1):8–12.
29.
JansonPAJubelirerSJWeinsteinMJDeykinD. Treatment of the bleeding tendency in uremia with cryoprecipitate. N Engl J Med. 1980;303(23):1318–1322.
30.
LivioMMannucciPMViganoG. Conjugated estrogens for the management of bleeding associated with renal failure. N Engl J Med. 1986;315(12):731–735.
31.
ViganoGGaspariFLocatelliMPusineriFBonatiMRemuzziG. Dose-effect and pharmacokinetics of estrogens given to correct bleeding time in uremia. Kidney Int. 1988;34(6):853–858.
32.
ViganoGZojaCCornaD. 17 beta-estradiol is the most active component of the conjugated estrogen mixture active on uremic bleeding by a receptor mechanism. J Pharmacol Exp Ther. 1990;252(1):344–348.
33.
LeslieSDToyPT. Laboratory hemostatic abnormalities in massively transfused patients given red blood cells and crystalloid. Am J Clin Pathol. 1991;96(6):770–773.
34.
LeviM. Current understanding of disseminated intravascular coagulation. Br J Haematol. 2004;124(5):567–576.
35.
LeviMTohCHThachilJWatsonHG. Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Committee for Standards in Haematology. Br J Haematol. 2009;145(1):24–33.
36.
MitraDJaffeEAWekslerBHajjarKASoderlandCLaurenceJ. Thrombotic thrombocytopenic purpura and sporadic hemolytic-uremic syndrome plasmas induce apoptosis in restricted lineages of human microvascular endothelial cells. Blood. 1997;89(4):1224–1234.
37.
MoakeJLRudyCKTrollJH. Unusually large plasma factor VIII: von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med. 1982;307(23):1432–1435.
38.
PlaimauerBZimmermannKVolkelD. Cloning, expression, and functional characterization of the von Willebrand factor-cleaving protease (ADAMTS13). Blood. 2002;100(10):3626–3632.
39.
RockGAShumakKHBuskardNA. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med. 1991;325(6):393–397.
CinesDBBusselJBLiebmanHALuning PrakET. The ITP syndrome: pathogenic and clinical diversity. Blood. 2009;113(26):6511–6521.
42.
WrightJFBlanchetteVSWangH. Characterization of platelet-reactive antibodies in children with varicella-associated acute immune thrombocytopenic purpura (ITP). Br J Haematol. 1996;95(1):145–152.
CookDCrowtherMMeadeM. Deep venous thrombosis in medical-surgical critically ill patients: prevalence, incidence, and risk factors. Crit Care Med. 2005;33(7):1565–1571.
45.
WarkentinTEKeltonJG. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med. 2001;344(17):1286–1292.
46.
GirolamiBPrandoniPStefaniPM. The incidence of heparin-induced thrombocytopenia in hospitalized medical patients treated with subcutaneous unfractionated heparin: a prospective cohort study. Blood. 2003;101(8):2955–2959.
47.
AhmedIMajeedAPowellR. Heparin induced thrombocytopenia: diagnosis and management update. Postgrad Med J. 2007;83(983):575–582.
48.
WarkentinTERobertsRSHirshJKeltonJG. Heparin-induced skin lesions and other unusual sequelae of the heparin-induced thrombocytopenia syndrome: a nested cohort study. Chest. 2005;127(5):1857–1861.
WarkentinTE. Think of HIT. Hematology Am Soc Hematol Educ Program. 2006;2006(1);408–414.
51.
WarkentinTE. An overview of the heparin-induced thrombocytopenia syndrome. Semin Thromb Hemost. 2004;30(3):273–283.
52.
WarkentinTE. New approaches to the diagnosis of heparin-induced thrombocytopenia. Chest. 2005;127(2 suppl):35S–45S.
53.
WarkentinTE. Heparin-induced thrombocytopenia: diagnosis and management. Circulation. 2004;110(18):e454–e458.
54.
GreinacherAJanssensUBergG. Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Heparin-Associated Thrombocytopenia Study (HAT) investigators. Circulation. 1999;100(6):587–593.
55.
GreinacherAVolpelHJanssensU. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study. Circulation. 1999;99(1):73–80.
56.
LewisBEWallisDELeyaFHurstingMJKeltonJG. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Arch Intern Med. 2003;163(15):1849–1856.
57.
LewisBEWallisDEBerkowitzSD. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation. 2001;103(14):1838–1843.
58.
SkrupkyLPSmithJRDealEN. Comparison of bivalirudin and argatroban for the management of heparin-induced thrombocytopenia. Pharmacotherapy. 2010;30(12):1229–1238.
59.
ArepallyGMOrtelTL. Clinical practice. Heparin-induced thrombocytopenia. N Engl J Med. 2006;355(8):809–817.
60.
WarkentinTESheppardJAHorsewoodPSimpsonPJMooreJCKeltonJG. Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood. 2000;96(5):1703–1708.
61.
WarkentinTEKeltonJG. A 14-year study of heparin-induced thrombocytopenia. Am J Med. 1996;101(5):502–507.
62.
AlvingBM. How I treat heparin-induced thrombocytopenia and thrombosis. Blood. 2003;101(1):31–37.
63.
KeelingDDavidsonSWatsonH. The management of heparin-induced thrombocytopenia. Br J Haematol. 2006;133(3):259–269.
64.
Zucker-FranklinDCaoYZ. Megakaryocytes of human immunodeficiency virus-infected individuals express viral RNA. Proc Natl Acad Sci U S A. 1989;86(14):5595–5599.
65.
ZauliGCataniLGibelliniD. Impaired survival of bone marrow GPIIb/IIa+ megakaryocytic cells as an additional pathogenetic mechanism of HIV-1-related thrombocytopenia. Br J Haematol. 1996;92(3):711–717.
66.
ThompsonGR 3rdLawrenceVACrawfordGE. HIV infection increases the risk of heparin-induced thrombocytopenia. Clin Infect Dis. 2007;45(10):1393–1396.
67.
GirardDEKumarKLMcAfeeJH. Hematologic effects of acute and chronic alcohol abuse. Hematol Oncol Clin North Am. 1987;1(2):321–334.
68.
O'ReillyRA. Splenomegaly in 2,505 patients at a large university medical center from 1913 to 1995. 1963 to 1995: 449 patients. West J Med. 1998;169(2):88–97.
69.
AsterRH. Pooling of platelets in the spleen: role in the pathogenesis of “hypersplenic” thrombocytopenia. J Clin Invest. 1966;45(5):645–657.
70.
DelaneyJAOpatrnyLBrophyJMSuissaS. Drug drug interactions between antithrombotic medications and the risk of gastrointestinal bleeding. CMAJ. 2007;177(4):347–351.
71.
SaviPNurdenPNurdenATLevy-ToledanoSHerbertJM. Clopidogrel: a review of its mechanism of action. Platelets. 1998;9(3-4):251–255.
72.
SharisPJCannonCPLoscalzoJ. The antiplatelet effects of ticlopidine and clopidogrel. Ann Intern Med. 1998;129(5):394–405.
73.
MarciniakSJJr. Mascelli MA, Furman MI, et al. An additional mechanism of action of abciximab: dispersal of newly formed platelet aggregates. Thromb Haemost. 2002;87(6):1020–1025.
74.
BrownDLFannCSChangCJ. Meta-analysis of effectiveness and safety of abciximab versus eptifibatide or tirofiban in percutaneous coronary intervention. Am J Cardiol. 2001;87(5):537–541.
75.
BillheimerJTDickerIBWynnR. Evidence that thrombocytopenia observed in humans treated with orally bioavailable glycoprotein IIb/IIIa antagonists is immune mediated. Blood. 2002;99(10):3540–3546.
76.
DasguptaHBlankenshipJCWoodGCFreyCMDemkoSLMenapaceFJ. Thrombocytopenia complicating treatment with intravenous glycoprotein IIb/IIIa receptor inhibitors: a pooled analysis. Am Heart J. 2000;140(2):206–211.
TchengJEKereiakesDJLincoffAM. Abciximab readministration: results of the ReoPro Readministration Registry. Circulation. 2001;104(8):870–875.
79.
ReeseJALiXHaubenM. Identifying drugs that cause acute thrombocytopenia: an analysis using 3 distinct methods. Blood. 2010;116(12):2127–2133.
80.
Pedersen-BjergaardUAndersenMHansenPB. Drug-specific characteristics of thrombocytopenia caused by non-cytotoxic drugs. Eur J Clin Pharmacol. 1998;54(9-10):701–706.
81.
WrightAJ. The penicillins. Mayo Clin Proc. 1999;74(3):290–307.
82.
ten BergMJHuismanASouvereinPC. Drug-induced thrombocytopenia: a population study. Drug Saf. 2006;29(8):713–721.
83.
WilsonAP. Comparative safety of teicoplanin and vancomycin. Int J Antimicrob Agents. 1998;10(2):143–152.
84.
RaoNZiranBHWagenerMMSantaERYuVL. Similar hematologic effects of long-term linezolid and vancomycin therapy in a prospective observational study of patients with orthopedic infections. Clin Infect Dis. 2004;38(8):1058–1064.
85.
BockMMuggenthalerKHSchmidtUHeimMU. Influence of antibiotics on posttransfusion platelet increment. Transfusion. 1996;36(11-12):952–954.
86.
GersonSLKaplanSLBrussJB. Hematologic effects of linezolid: summary of clinical experience. Antimicrob Agents Chemother. 2002;46(8):2723–2726.
87.
LinYHWuVCTsaiIJ. High frequency of linezolid-associated thrombocytopenia among patients with renal insufficiency. Int J Antimicrob Agents. 2006;28(4):345–351.
88.
WuVCWangYTWangCY. High frequency of linezolid-associated thrombocytopenia and anemia among patients with end-stage renal disease. Clin Infect Dis. 2006;42(1):66–72.
89.
WadeEERebuckJAHealeyMARogersFB. H(2) antagonist-induced thrombocytopenia: is this a real phenomenon?. Intensive Care Med. 2002;28(4):459–465.
90.
CawleyMJWittbrodtETBoyceEGSkaarDJ. Potential risk factors associated with thrombocytopenia in a surgical intensive care unit. Pharmacotherapy. 1999;19(1):108–113.
91.
SharmaBSharmaMMajumderMSteierWSangalAKalawarM. Thrombocytopenia in septic shock patients–a prospective observational study of incidence, risk factors and correlation with clinical outcome. Anaesth Intensive Care. 2007;35(6):874–880.
92.
FrancoisBTrimoreauFVignonPFixePPraloranVGastinneH. Thrombocytopenia in the sepsis syndrome: role of hemophagocytosis and macrophage colony-stimulating factor. Am J Med. 1997;103(2):114–120.
93.
MavrommatisACTheodoridisTOrfanidouARoussosCChristopoulou-KokkinouVZakynthinosS. Coagulation system and platelets are fully activated in uncomplicated sepsis. Crit Care Med. 2000;28(2):451–457.
94.
CorriganJJJrRayWLMayN. Changes in the blood coagulation system associated with septicemia. N Engl J Med. 1968;279(16):851–856.
95.
VanderschuerenSDe WeerdtAMalbrainM. Thrombocytopenia and prognosis in intensive care. Crit Care Med. 2000;28(6):1871–1876.
96.
HolzerMBernardSAHachimi-IdrissiSRoineROSterzFMullnerM. Hypothermia for neuroprotection after cardiac arrest: systematic review and individual patient data meta-analysis. Crit Care Med. 2005;33(2):414–418.
HemmenTMLydenPD. Induced hypothermia for acute stroke. Stroke. 2007;38(2 suppl):794–799.
99.
CliftonGLMillerERChoiSC. Lack of effect of induction of hypothermia after acute brain injury. N Engl J Med. 2001;344(8):556–563.
100.
DmelloDCruz-FloresSMatuschakGM. Moderate hypothermia with intracranial pressure monitoring as a therapeutic paradigm for the management of acute liver failure: a systematic review. Intensive Care Med. 2010;36(2):210–213.
101.
SeuleMAMuroiCMinkSYonekawaYKellerE. Therapeutic hypothermia in patients with aneurysmal subarachnoid hemorrhage, refractory intracranial hypertension, or cerebral vasospasm. Neurosurgery. 2009;64(1):86–92.discussion 92-83
102.
WenselRHBigelowWG. The use of heparin to minimize thrombocytopenia and bleeding tendency during hypothermia. Surgery. 1959;45(2):223–228.
103.
CohenIJAmirJGedaliahARachmalAGorodischerRZaizovR. Thrombocytopenia of neonatal cold injury. J Pediatr. 1984;104(4):620–622.
104.
WyssMBabelJFRougeJCBouvierCA. Haemostatic changes during open heart surgery with extracorporeal circulation and deep hypothermia in children. Anaesthesist. 1982;31(2):82–86.
105.
CohenIJ. Room temperature ADP-induced first-stage hyperaggregation of human platelets: the cause of rewarming deaths by thrombocytopenia in neonatal cold injury. Pediatr Hematol Oncol. 1991;8(1):61–67.
106.
ZhangJNWoodJBergeronAL. Effects of low temperature on shear-induced platelet aggregation and activation. J Trauma. 2004;57(2):216–223.
107.
SlichterSJBolgianoDJonesMK. Viability and function of 8-day-stored apheresis platelets. Transfusion. 2006;46(10):1763–1769.
108.
YomtovianRLazarusHMGoodnoughLTHirschlerNVMorrisseyAMJacobsMR. A prospective microbiologic surveillance program to detect and prevent the transfusion of bacterially contaminated platelets. Transfusion. 1993;33(11):902–909.
109.
ShanwellADiedrichBFalkerC. Paired in vitro and in vivo comparison of apheresis platelet concentrates stored in platelet additive solution for 1 versus 7 days. Transfusion. 2006;46(6):973–979.
110.
BishopJFMcGrathKWolfMM. Clinical factors influencing the efficacy of pooled platelet transfusions. Blood. 1988;71(2):383–387.
111.
SchifferCAAndersonKCBennettCL. Platelet transfusion for patients with cancer: clinical practice guidelines of the American society of clinical oncology. J Clin Oncol. 2001;19(5):1519–1538.
112.
LiumbrunoGBennardelloFLattanzioAPiccoliPRossettiG. Recommendations for the transfusion of plasma and platelets. Blood Transfus. 2009;7(2):132–150.
